Jay Sial - 15 Jul 2021 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role
Chief Administrative Officer
Signature
/s/Mark L. Johnson, Attorney-in-Fact for Jay Sial
Issuer symbol
ERNA
Transactions as of
15 Jul 2021
Net transactions value
$0
Form type
4
Filing time
19 Jul 2021, 21:30:35 UTC
Next filing
17 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA Stock Option Award $0 +71,000 $0.000000 71,000 15 Jul 2021 Common Stock 71,000 $10.31 Direct F1
transaction ERNA Restricted Stock Unit Award $0 +35,700 $0.000000 35,700 15 Jul 2021 Common Stock 35,700 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on July 15, 2022, and 1/36 of the remaining shares covered thereby vesting on the 15th day of each calendar month from August 2022 through July 15, 2025, subject to continued service through each vesting date.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 The RSU Grant vests and becomes exercisable in four equal installments on July 15 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Mr. Sial's Executive Employment Agreement, dated as of July 6, 2021 and effective July 15, 2021), subject to continued service through each vesting date.

Remarks:

Chief Administrative Officer